| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from JNJ grap… |
| JNJ |
Johnson & Johnson |
72%
|
uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SYRE graph: uld any of our product candidates… |
| SNYNF |
Sanofi |
72%
|
uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/… |
| AEGLEA-BIOTHERAPEUTICS-HOLDINGS-LLC |
AEGLEA-BIOTHERAPEUTICS-HOLDINGS-LLC |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| AEGLEA-BIOTHERAPEUTICS-INC |
AEGLEA-BIOTHERAPEUTICS-INC |
62%
|
ubjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by commu… |
| ASPEN-MERGER-SUB-I-INC |
ASPEN-MERGER-SUB-I-INC |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| COMPANY-PARAGON-THERAPEUTICS-INC |
COMPANY-PARAGON-THERAPEUTICS-INC |
62%
|
f underwriting discounts and other offering costs (the “October 2025 Offering”). The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025. On… |
| COMPANY-SEQUOIA-MERGER-SUB-II-LLC |
COMPANY-SEQUOIA-MERGER-SUB-II-LLC |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
could inadvertently be incorporated into AI model training datasets or disclosed through model inference. As global laws and guidance surrounding AI systems continue to evolve, noncompliance could re… |
| EQUINITI-TRUST-COMPANY-LLC |
EQUINITI-TRUST-COMPANY-LLC |
62%
|
ial materials, study monitoring and data analysis that could materially adversely impact our business, results of operations and overall financial performance in future periods. As of the filing date… |
| EU-CLINICAL-TRIALS-EXPERT-GROUP |
EU-CLINICAL-TRIALS-EXPERT-GROUP |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| FAIRMOUNT-FUNDS-MANAGEMENT-LLC |
FAIRMOUNT-FUNDS-MANAGEMENT-LLC |
62%
|
f underwriting discounts and other offering costs (the “October 2025 Offering”). The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025. On… |
| LIMITED-LIABILITY-COMPANY |
LIMITED-LIABILITY-COMPANY |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| PARAPYRE-HOLDING-LLC |
PARAPYRE-HOLDING-LLC |
62%
|
f underwriting discounts and other offering costs (the “October 2025 Offering”). The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025. On… |
| PRESENTATION-SPYRE-THERAPEUTICS-INC |
PRESENTATION-SPYRE-THERAPEUTICS-INC |
62%
|
ubjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by commu… |
| TRUST-COMPANY-LLC |
TRUST-COMPANY-LLC |
62%
|
ial materials, study monitoring and data analysis that could materially adversely impact our business, results of operations and overall financial performance in future periods. As of the filing date… |
| USA-LLC |
USA-LLC |
62%
|
Sale of In-Process Research and Development Asset . During the three months ended March 31, 2026, the Company recognized a gain of $30.0 million for an achieved milestone related to the 2023 sale of … |
